• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌干细胞:问题多于答案。

Ovarian cancer stem cells more questions than answers.

机构信息

Department of Medical Oncology (452), Radboud University Medical Center, PO 9101, 6500 HB Nijmegen, The Netherlands.

出版信息

Semin Cancer Biol. 2017 Jun;44:67-71. doi: 10.1016/j.semcancer.2017.04.009. Epub 2017 Apr 24.

DOI:10.1016/j.semcancer.2017.04.009
PMID:28450177
Abstract

Epithelial ovarian cancer is a highly lethal disease, which is usually diagnosed at a late stage with extensive metastases in the abdominal cavity. Ovarian cancer either develops from the ovarian surface epithelium (OSE) or from serous intra-epithelial carcinoma (STIC). Primary therapy consists of debulking surgery and platinum based chemotherapy. The success of debulking surgery depends on surgical skills but also on the gene signature of the tumour. Debulking surgery combined with first line platinum based chemotherapy, frequently leads to complete remission. However, most ovarian cancers relapse. Once the disease has relapsed, the interval between subsequent therapies decreases steadily due to rapid progression and therapy resistance. Research on therapy resistance of ovarian cancer is frequently devoted to genetic alterations in cancer cells, leading to drug inactivation, enhanced DNA repair mechanisms and intracellular pathway derangements. However the knowledge of ovarian cancer stem cells (OCSC) and the role they play in the development of cancer and therapy resistance is sparse. In this review current knowledge on the characteristics of OCSCs and the micro environmental mechanisms leading to the development or activation of OCSCs resulting in ovarian cancer is reviewed. Moreover the role of OCSC in both surgical and systemic therapy resistance and the relation with epithelial mesenchymal transformation (EMT) is discussed, as are micro-environmental signals leading to OCSC or EMT activation.

摘要

上皮性卵巢癌是一种高度致命的疾病,通常在晚期诊断,伴有腹腔广泛转移。卵巢癌要么源自卵巢表面上皮(OSE),要么源自浆液性上皮内癌(STIC)。初始治疗包括肿瘤减灭术和铂类为基础的化疗。肿瘤减灭术的成功不仅取决于手术技能,还取决于肿瘤的基因特征。肿瘤减灭术联合一线铂类化疗,常可导致完全缓解。然而,大多数卵巢癌会复发。一旦疾病复发,由于进展迅速和耐药性,后续治疗的间隔时间会稳步缩短。卵巢癌耐药性的研究通常集中在癌细胞的遗传改变上,导致药物失活、增强的 DNA 修复机制和细胞内途径紊乱。然而,关于卵巢癌干细胞(OCSC)的知识以及它们在癌症发展和耐药性中的作用还很匮乏。本综述回顾了 OCSC 的特征以及导致 OCSC 发展或激活从而导致卵巢癌的微环境机制。此外,还讨论了 OCSC 在手术和全身治疗耐药性中的作用,以及与上皮间质转化(EMT)的关系,以及导致 OCSC 或 EMT 激活的微环境信号。

相似文献

1
Ovarian cancer stem cells more questions than answers.卵巢癌干细胞:问题多于答案。
Semin Cancer Biol. 2017 Jun;44:67-71. doi: 10.1016/j.semcancer.2017.04.009. Epub 2017 Apr 24.
2
NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.NANOG通过激活上皮性卵巢癌中的STAT3信号通路来调控上皮-间质转化及化疗耐药性。
Tumour Biol. 2016 Jul;37(7):9671-80. doi: 10.1007/s13277-016-4848-x. Epub 2016 Jan 22.
3
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.铂类化疗耐药与上皮性卵巢癌中上皮间质转化有关。
Eur J Cancer. 2013 Jan;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026. Epub 2012 Aug 13.
4
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.高级别卵巢浆液性癌中的癌症干细胞、上皮-间质转化和药物耐药性。
Hum Pathol. 2013 Nov;44(11):2373-84. doi: 10.1016/j.humpath.2013.05.001. Epub 2013 Jul 11.
5
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.在非浆液性上皮性卵巢癌患者中,FOXM1表达与化疗耐药及不良预后显著相关。
J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.
6
CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.CD24表达是预测临床结果的标志物,并通过Akt和ERK途径调节卵巢癌中的上皮-间质转化。
Oncol Rep. 2017 Jun;37(6):3189-3200. doi: 10.3892/or.2017.5583. Epub 2017 Apr 19.
7
LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.LIM 同源盒转录因子 1,α(LMX1A)抑制上皮性卵巢癌的肿瘤发生、上皮-间充质转化和干细胞样特性。
Gynecol Oncol. 2013 Mar;128(3):475-82. doi: 10.1016/j.ygyno.2012.12.018. Epub 2012 Dec 24.
8
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.癌性卵巢干细胞:治疗的模糊靶点,但与化疗耐药相关。
J Cell Biochem. 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317.
9
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.高级别浆液性卵巢癌一线化疗后的基因异质性。
Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.
10
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.DYRK2通过降解卵巢浆液性腺癌中的Snail来调控上皮-间质转化和化学敏感性。
Tumour Biol. 2015 Aug;36(8):5913-23. doi: 10.1007/s13277-015-3264-y. Epub 2015 Feb 25.

引用本文的文献

1
AAV for ovarian cancer gene therapy.用于卵巢癌基因治疗的腺相关病毒
Cancer Gene Ther. 2025 Jun 20. doi: 10.1038/s41417-025-00926-4.
2
Assessment of knowledge and awareness about ovarian cancer and its risk factors among women in Jazan, Saudi Arabia: a cross-sectional study.沙特阿拉伯吉赞地区女性对卵巢癌及其危险因素的知识与认知评估:一项横断面研究
Saudi Pharm J. 2025 Apr 16;33(1-2):1. doi: 10.1007/s44446-025-00002-w.
3
AKT1 as a therapeutic target for platinum-resistant SOX2 positive ovarian cancer cells.AKT1作为铂耐药的SOX2阳性卵巢癌细胞的治疗靶点。
Sci Rep. 2025 Apr 29;15(1):15096. doi: 10.1038/s41598-025-92036-2.
4
HBO1 determines epithelial-mesenchymal transition and promotes immunotherapy resistance in ovarian cancer cells.HBO1决定卵巢癌细胞的上皮-间质转化并促进免疫治疗抗性。
Cell Oncol (Dordr). 2025 Apr 14. doi: 10.1007/s13402-025-01055-8.
5
Despicable role of epithelial-mesenchymal transition in breast cancer metastasis: Exhibiting restorative regimens.上皮-间质转化在乳腺癌转移中的可鄙作用:展示恢复性方案。
Cancer Pathog Ther. 2024 Jan 12;3(1):30-47. doi: 10.1016/j.cpt.2024.01.001. eCollection 2025 Jan.
6
A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.一种针对卵巢癌靶向药物递送的纳米级天然药物递送系统:作用机制、应用启示和未来潜力。
Front Immunol. 2024 Oct 11;15:1427573. doi: 10.3389/fimmu.2024.1427573. eCollection 2024.
7
Knocking down RAD51AP1 enhances chemosensitivity by inhibiting the self-renewal of CD133 positive ovarian cancer stem-like cells.敲低RAD51AP1可通过抑制CD133阳性卵巢癌干细胞样细胞的自我更新来增强化学敏感性。
Discov Oncol. 2024 Sep 5;15(1):410. doi: 10.1007/s12672-024-01258-9.
8
Long Non-coding RNA DNM3OS: Pathogenic Roles and Molecular Mechanisms in Pathophysiological Processes.长链非编码 RNA DNM3OS:在病理生理过程中的致病作用和分子机制。
Curr Med Chem. 2024;31(29):4687-4702. doi: 10.2174/0109298673280484240101070607.
9
Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.癌症侧群干细胞在卵巢癌血管生成中的作用。
Med Princ Pract. 2024;33(5):403-413. doi: 10.1159/000539642. Epub 2024 Jul 26.
10
Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology.通过噬菌体展示技术在卵巢癌免疫诊断和治疗方面的进展。
Front Immunol. 2024 May 28;15:1402862. doi: 10.3389/fimmu.2024.1402862. eCollection 2024.